Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat replacement after inadequate response to PDE-5 inhibitors in CHD-associated pulmonary arterial hypertension
ChiCTR2500096733Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by The Second Xiangya Hospital. Primary endpoint: Six-minute walking distance. Started Sep 2024; status: recruiting.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ChiCTR2500096733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096733.